Guillain-Barré Syndrome Following Influenza Vaccines Affords Opportunity to Improve Vaccine Confidence

J Infect Dis. 2021 Feb 13;223(3):355-358. doi: 10.1093/infdis/jiaa544.

Daniel A Salmon^{1

2

3}, Matthew Z Dudley^{1

3}, Bruce C Carleton^{4

5

6}

¹ Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
² Department of Health, Behavior and Society, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
³ Institute for Vaccine Safety, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
⁴ Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, Canada.
⁵ British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, Canada.
⁶ Pharmaceutical Outcomes Program, British Columbia Children's Hospital, Vancouver, Canada.

No abstract available

Keywords: Guillain-Barré syndrome; adversomics; influenza vaccine; vaccine confidence; vaccine hesitancy; vaccine safety; vaccinomics.

Publication types